Skip to main
INKT
INKT logo

MiNK Therapeutics (INKT) Stock Forecast & Price Target

MiNK Therapeutics (INKT) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MiNK Therapeutics Inc has seen a significant increase in its stock value, with shares rising over 400% recently, which contrasts sharply with the 2% increase in the Nasdaq Biotechnology Index (NBI), indicating strong investor interest. The company's innovative allogeneic iNKT cell therapies not only promise scalable and cost-effective manufacturing but also leverage a dual mechanism of action by retaining essential tumor-homing properties while gaining enhanced antigen-specific capabilities. Furthermore, the company's potential to attract additional capital for ongoing and future clinical trials provides a solid foundation for its continued growth and positive outlook in the biopharmaceutical sector.

Bears say

MiNK Therapeutics faces several fundamental risks that contribute to a negative outlook on its stock, including potential safety issues in its clinical and preclinical programs, which could adversely impact investor confidence. The company anticipates requiring approximately $55 million in additional financing, with a projected cash runway extending only into mid-2025, raising concerns about its financial stability. Furthermore, there are significant risks related to competition, potential regulatory challenges, and the possibility of de-listing if share prices fall below $1, which collectively undermine the company's growth prospects.

MiNK Therapeutics (INKT) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MiNK Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MiNK Therapeutics (INKT) Forecast

Analysts have given MiNK Therapeutics (INKT) a Strong Buy based on their latest research and market trends.

According to 1 analysts, MiNK Therapeutics (INKT) has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MiNK Therapeutics (INKT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.